{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T00:05:24Z","timestamp":1744157124286,"version":"3.40.3"},"publisher-location":"New York, NY","reference-count":31,"publisher":"Springer New York","isbn-type":[{"type":"print","value":"9781493933853"},{"type":"electronic","value":"9781493933877"}],"license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016]]},"DOI":"10.1007\/978-1-4939-3387-7_11","type":"book-chapter","created":{"date-parts":[[2016,4,14]],"date-time":"2016-04-14T11:08:16Z","timestamp":1460632096000},"page":"221-244","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Methods to Evaluate Novel Hepatitis C Virus Vaccines"],"prefix":"10.1007","author":[{"given":"Gustaf","family":"Ahl\u00e9n","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars","family":"Frelin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,4,14]]},"reference":[{"key":"11_CR1","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1002\/hep.26141","volume":"57","author":"K Mohd Hanafiah","year":"2013","unstructured":"Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST (2013) Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 57:1333\u20131342","journal-title":"Hepatology"},{"key":"11_CR2","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1038\/nm.3184","volume":"19","author":"DL Thomas","year":"2013","unstructured":"Thomas DL (2013) Global control of hepatitis C: where challenge meets opportunity. Nature Med 19:850\u2013858","journal-title":"Nature Med"},{"key":"11_CR3","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa1306218","volume":"370","author":"MS Sulkowski","year":"2014","unstructured":"Sulkowski MS, Gardiner DF, Rodriguez-Torres M, Reddy KR et al (2014) Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. New Engl J Med 370:211\u2013221","journal-title":"New Engl J Med"},{"key":"11_CR4","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1056\/NEJMoa1315722","volume":"370","author":"JJ Feld","year":"2014","unstructured":"Feld JJ, Kowdley KV, Coakley E, Sigal S et al (2014) Treatment of HCV with ABT-450\/r\u2013ombitasvir and dasabuvir with ribavirin. New Engl J Med 370:1594\u20131603","journal-title":"New Engl J Med"},{"key":"11_CR5","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.drup.2013.06.001","volume":"16","author":"G Ahlen","year":"2013","unstructured":"Ahlen G, Frelin L, Brenndorfer ED, Brass A et al (2013) Containing \u201cThe Great Houdini\u201d of viruses: combining direct acting antivirals with the host immune response for the treatment of chronic hepatitis C. Drug Resist Updat 16:60\u201367","journal-title":"Drug Resist Updat"},{"key":"11_CR6","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1002\/hep.27278","volume":"60","author":"B Callendret","year":"2014","unstructured":"Callendret B, Eccleston HB, Hall S, Satterfield W et al (2014) T-cell immunity and hepatitis C virus reinfection after cure of chronic hepatitis C with an interferon-free antiviral regimen in a chimpanzee. Hepatology 60:1531\u20131540","journal-title":"Hepatology"},{"key":"11_CR7","doi-asserted-by":"publisher","first-page":"115ra111","DOI":"10.1126\/scitranslmed.3003155","volume":"4","author":"E Barnes","year":"2012","unstructured":"Barnes E, Folgori A, Capone S, Swadling L et al (2012) Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man. Sci Transl Med 4:115ra111","journal-title":"Sci Transl Med"},{"key":"11_CR8","doi-asserted-by":"publisher","first-page":"261ra153","DOI":"10.1126\/scitranslmed.3009185","volume":"6","author":"L Swadling","year":"2014","unstructured":"Swadling L, Capone S, Antrobus RD, Brown A et al (2014) A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory. Sci Transl Med 6:261ra153","journal-title":"Sci Transl Med"},{"key":"11_CR9","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1038\/mt.2013.119","volume":"21","author":"O Weiland","year":"2013","unstructured":"Weiland O, Ahlen G, Diepolder H, Jung MC et al (2013) Therapeutic DNA vaccination using in vivo electroporation followed by standard of care therapy in patients with genotype 1 chronic hepatitis C. Mol Therapy 21:1796\u20131805","journal-title":"Mol Therapy"},{"key":"11_CR10","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1053\/j.gastro.2014.03.007","volume":"147","author":"AM Bisceglie Di","year":"2014","unstructured":"Di Bisceglie AM, Janczweska-Kazek E, Habersetzer F et al (2014) Efficacy of immunotherapy with TG4040, peg-interferon, and ribavirin in a Phase 2 study of patients with chronic HCV infection. Gastroenterology 147:119\u2013131","journal-title":"Gastroenterology"},{"key":"11_CR11","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1053\/j.gastro.2011.06.009","volume":"141","author":"F Habersetzer","year":"2011","unstructured":"Habersetzer F, Honnet G, Bain C, Maynard-Muet M et al (2011) A poxvirus vaccine is safe, induces T-cell responses, and decreases viral load in patients with chronic hepatitis C. Gastroenterology 141:890\u2013899","journal-title":"Gastroenterology"},{"key":"11_CR12","doi-asserted-by":"publisher","first-page":"2943","DOI":"10.1016\/j.vaccine.2012.02.070","volume":"30","author":"CS Klade","year":"2012","unstructured":"Klade CS, Schuller E, Boehm T, von Gabain A, Manns MP (2012) Sustained viral load reduction in treatment-naive HCV genotype 1 infected patients after therapeutic peptide vaccination. Vaccine 30:2943\u20132950","journal-title":"Vaccine"},{"key":"11_CR13","doi-asserted-by":"publisher","first-page":"5142","DOI":"10.1016\/j.vaccine.2009.06.027","volume":"27","author":"H Wedemeyer","year":"2009","unstructured":"Wedemeyer H, Schuller E, Schlaphoff V, Stauber RE et al (2009) Therapeutic vaccine IC41 as late add-on to standard treatment in patients with chronic hepatitis C. Vaccine 27:5142\u20135151","journal-title":"Vaccine"},{"key":"11_CR14","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1038\/sj.gt.3302184","volume":"11","author":"L Frelin","year":"2004","unstructured":"Frelin L, Ahlen G, Alheim M, Weiland O et al (2004) Codon optimization and mRNA amplification effectively enhances the immunogenicity of the hepatitis C virus nonstructural 3\/4A gene. Gene Ther 11:522\u2013533","journal-title":"Gene Ther"},{"key":"11_CR15","doi-asserted-by":"publisher","first-page":"5107","DOI":"10.4049\/jimmunol.1001790","volume":"186","author":"A Chen","year":"2011","unstructured":"Chen A, Ahlen G, Brenndorfer ED, Brass A et al (2011) Heterologous T cells can help restore function in dysfunctional hepatitis C virus nonstructural 3\/4A-specific T cells during therapeutic vaccination. J Immunol 186:5107\u20135118","journal-title":"J Immunol"},{"key":"11_CR16","unstructured":"Levander S, S\u00e4llberg M, Ahl\u00e9n G, Frelin L. A non-human hepadnaviral adjuvant for hepatitis C virus-based DNA vaccines. Submitted for publication."},{"key":"11_CR17","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1038\/mt.2014.233","volume":"23","author":"A Brass","year":"2015","unstructured":"Brass A, Frelin L, Milich DR, Sallberg M, Ahlen G (2015) Functional aspects of intrahepatic Hepatitis B Virus-specific T cells induced by therapeutic DNA vaccination. Mol Therapy 23:578\u2013590","journal-title":"Mol Therapy"},{"key":"11_CR18","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/978-1-60761-585-9_19","volume":"626","author":"MG Tovey","year":"2010","unstructured":"Tovey MG, Lallemand C (2010) Adjuvant activity of cytokines. Methods Mol Biol 626:287\u2013309","journal-title":"Methods Mol Biol"},{"key":"11_CR19","doi-asserted-by":"publisher","first-page":"3882","DOI":"10.4049\/jimmunol.175.6.3882","volume":"175","author":"SE Applequist","year":"2005","unstructured":"Applequist SE, Rollman E, Wareing MD, Liden M et al (2005) Activation of innate immunity, inflammation, and potentiation of DNA vaccination through mammalian expression of the TLR5 agonist flagellin. J Immunol 175:3882\u20133891","journal-title":"J Immunol"},{"key":"11_CR20","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1038\/11726","volume":"17","author":"LJ Branden","year":"1999","unstructured":"Branden LJ, Mohamed AJ, Smith CI (1999) A peptide nucleic acid-nuclear localization signal fusion that mediates nuclear transport of DNA. Nature Biotechnol 17:784\u2013787","journal-title":"Nature Biotechnol"},{"key":"11_CR21","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s00430-014-0384-8","volume":"204","author":"M Sallberg","year":"2015","unstructured":"Sallberg M, Frelin L, Ahlen G, Sallberg-Chen M (2015) Electroporation for therapeutic DNA vaccination in patients. Medical Microbiol Immunol 204:131\u2013135","journal-title":"Medical Microbiol Immunol"},{"key":"11_CR22","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1126\/science.8456302","volume":"259","author":"JB Ulmer","year":"1993","unstructured":"Ulmer JB, Donnelly JJ, Parker SE, Rhodes GH et al (1993) Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 259:1745\u20131749","journal-title":"Science"},{"key":"11_CR23","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1086\/515613","volume":"178","author":"RR MacGregor","year":"1998","unstructured":"MacGregor RR, Boyer JD, Ugen KE, Lacy KE et al (1998) First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response. J Infect Dis 178:92\u2013100","journal-title":"J Infect Dis"},{"key":"11_CR24","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1016\/S0140-6736(97)09440-3","volume":"351","author":"S Calarota","year":"1998","unstructured":"Calarota S, Bratt G, Nordlund S, Hinkula J et al (1998) Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients. Lancet 351:1320\u20131325","journal-title":"Lancet"},{"key":"11_CR25","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1038\/nbt0998-867","volume":"16","author":"H Aihara","year":"1998","unstructured":"Aihara H, Miyazaki J (1998) Gene transfer into muscle by electroporation in vivo. Nature Biotechnol 16:867\u2013870","journal-title":"Nature Biotechnol"},{"key":"11_CR26","doi-asserted-by":"publisher","first-page":"4741","DOI":"10.4049\/jimmunol.179.7.4741","volume":"179","author":"G Ahlen","year":"2007","unstructured":"Ahlen G, Soderholm J, Tjelle T, Kjeken R, Frelin L et al (2007) In vivo electroporation enhances the immunogenicity of hepatitis C virus nonstructural 3\/4A DNA by increased local DNA uptake, protein expression, inflammation, and infiltration of CD3+ T cells. J Immunol 179:4741\u20134753","journal-title":"J Immunol"},{"key":"11_CR27","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.4161\/hv.22062","volume":"8","author":"A Gothelf","year":"2012","unstructured":"Gothelf A, Gehl J (2012) What you always needed to know about electroporation based DNA vaccines. Human Vaccines Immunother 8:1694\u20131702","journal-title":"Human Vaccines Immunother"},{"key":"11_CR28","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/978-1-62703-110-3_20","volume":"940","author":"G Ahlen","year":"2013","unstructured":"Ahlen G, Sallberg M, Frelin L (2013) Methods for monitoring gene gun-induced HBV- and HCV-specific immune responses in mouse models. Methods Mol Biol 940:239\u2013267","journal-title":"Methods Mol Biol"},{"key":"11_CR29","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1093\/infdis\/jit267","volume":"208","author":"A Fournillier","year":"2013","unstructured":"Fournillier A, FrelinL JE, Ahlen G et al (2013) A heterologous prime\/boost vaccination strategy enhances the immunogenicity of therapeutic vaccines for hepatitis C virus. J Infect Dis 208:1008\u20131019","journal-title":"J Infect Dis"},{"key":"11_CR30","doi-asserted-by":"publisher","first-page":"7492","DOI":"10.1128\/JVI.02743-07","volume":"82","author":"Y Lin","year":"2008","unstructured":"Lin Y, Kwon T, Polo J, Zhu YF et al (2008) Induction of broad CD4+ and CD8+ T-cell responses and cross-neutralizing antibodies against hepatitis C virus by vaccination with Th1-adjuvanted polypeptides followed by defective alphaviral particles expressing envelope glycoproteins gpE1 and gpE2 and nonstructural proteins 3, 4, and 5. J Virol 82:7492\u20137503","journal-title":"J Virol"},{"key":"11_CR31","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1128\/JVI.77.1.382-390.2003","volume":"77","author":"P Pancholi","year":"2003","unstructured":"Pancholi P, Perkus M, Tricoche N, Liu Q, Prince AM (2003) DNA immunization with hepatitis C virus (HCV) polycistronic genes or immunization by HCV DNA priming-recombinant canarypox virus boosting induces immune responses and protection from recombinant HCV-vaccinia virus infection in HLA-A2.1-transgenic mice. J Virol 77:382\u2013390","journal-title":"J Virol"}],"container-title":["Methods in Molecular Biology","Vaccine Design"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-4939-3387-7_11","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T16:53:35Z","timestamp":1692291215000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-1-4939-3387-7_11"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"ISBN":["9781493933853","9781493933877"],"references-count":31,"URL":"https:\/\/doi.org\/10.1007\/978-1-4939-3387-7_11","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"type":"print","value":"1064-3745"},{"type":"electronic","value":"1940-6029"}],"subject":[],"published":{"date-parts":[[2016]]},"assertion":[{"value":"14 April 2016","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}